La chaîne d'options affiche les données clés des options sur actions de KalVista Pharma à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour KalVista Pharma..

KalVista Pharma (NASDAQ:KALV) Stock, Chaîne d'Options

KALVISTA PHARMACEUTICALS INC

KalVista Pharma

KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.

KalVista Pharmaceuticals, Inc. - Common Stock

KalVista Pharmaceuticals Inc

Wells Fargo analyst Sam Reid maintains Core &amp; Main (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNM#NYSE">CNM</a>) with a Overweight and raises the price target from $65 to $70.

News

Price Target

Analyst Ratings

Wells Fargo Maintains Overweight on Core & Main, Raises Price Target to $70

Contracts

TTEK

Tetra Tech Selected For $248M Contract From  U.S. Army Corps of Engineers, Europe District To Provide Architect-Engineer Services For U.S. Military Installations

Evercore ISI Group analyst Vijay Kumar maintains Zimmer Biomet Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) with a In-Line and lowers the price target from $102 to $96.

Evercore ISI Group Maintains In-Line on Zimmer Biomet Holdings, Lowers Price Target to $96

Wells Fargo analyst Jason Haas maintains MSCI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSCI#NYSE">MSCI</a>) with a Equal-Weight and raises the price target from $530 to $578.

MSCI

Wells Fargo Maintains Equal-Weight on MSCI, Raises Price Target to $578

Vicon Industries, a subsidiary of Cemtrex Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CETX#NASDAQ">CETX</a>, CETXP))) and a leading provider of advanced security and surveillance solutions, today announced that it has secured a follow-on order exceeding $1.2 million to support a major Midwestern county government security upgrade project. The order was placed through a long-standing global systems integration partner.

CETX

Cemtrex's Vicon Industries Secures Follow-On Order Exceeding $1.2M To Support Midwestern County Government Security Upgrade Project

Benchmark analyst Josh Sullivan maintains Kratos Defense &amp; Security (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTOS#NASDAQ">KTOS</a>) with a Buy and raises the price target from $48 to $50.

KTOS

Benchmark Maintains Buy on Kratos Defense & Security, Raises Price Target to $50

Evercore ISI Group analyst Vijay Kumar maintains Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Outperform and lowers the price target from $500 to $480.

Evercore ISI Group Maintains Outperform on Thermo Fisher Scientific, Lowers Price Target to $480

Tesla's <a href="https://www.benzinga.com/markets/equities/25/07/46259886/elon-musks-tesla-is-a-multi-trillion-dollar-opportunity-but-short-term-outlook-is-shaky-says-expert">new robotaxi service</a> might drive itself — but if it starts to rain, you could still get kicked to the curb.
YouTuber and Tesla fan Ellie Sheriff took her first ride in the company's self-driving ride-hail vehicle in Austin, Texas, and documented the <a href="https://youtu.be/edEpCjk6Skw?si=bKhZU3GT7vnyub4J">whole experience on her channel "Ellie in Space."</a> She was excited, nervous, and admittedly impressed — until the trip took an unexpected detour.
At first, everything felt like a glimpse of the future. Then came the moment no rider expects: a sudden request to exit, mid-trip, due to incoming weather.
Don't Miss:
<ul class="wp-block-list">
<li>Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"> Here&#8217;s how you can earn passive income with just $10.</a></li>
<li>$100k+ in investable assets? <a href="https://www.benzinga.com/money/wiseradvisor-retirement-planning">Match with a fiduciary advisor for free to learn how you can maximize your retirement and save on taxes</a> – no cost, no obligation.</li>
</ul>
"So we had to get out of the robotaxi ‘cuz weather is coming in," Sheriff explained, standing in what she described as "a park with no cover" as the wind picked up. Moments later, the vehicle drove away, and her app showed a dreaded message: "high demand."
"Now we have to try to summon it again," she said. "Can't quite get a ride yet."
The incident came just minutes into her first ride, which had been mostly smooth up to that point. The robotaxi, part of Tesla's early rollout, still includes a human "safety observer" in the front passenger seat — so it's not quite the full-autonomy experience of <a href="https://www.benzinga.com/markets/tech/25/06/46133153/tesla-robotaxi-has-a-major-advantage-over-rivals-waymo-and-zoox-says-gary-black-could-be-very-significant">competitors like Waymo</a>, but it's getting there.
Still, the rain warning caused the system to shut down the trip entirely — a flaw Sheriff didn't ignore.
"I don't want to just be a Tesla raw-raw cheerleader. It is very cool," she said. "However, this is a limitation currently, how it is. You shouldn't have to terminate the service ‘cuz it's about to rain."
Trending: The secret weapon in billionaire investor portfolios that you almost certainly don't own yet. <a href="https://www.benzinga.com/money/masterworks">See which asset class has outpaced the S&amp;P 500 (1995-2024) – and with near-zero correlation.</a>
She also mentioned another glitch: "It did one weird thing on my first ride, which was just randomly going into a parking lot."
After a few minutes stranded in the open, she finally got another robotaxi — the same one, in fact — and was taken back to where she started.
To be clear, Sheriff didn't walk away disappointed. In fact, she praised the ride for being uneventful — in a good way.
"It was actually remarkable how boring it was by the end," she said. "And that's how you want it to be."
She added, "Normally you see me on a plane during turbulence, I'm very anxious… but this, I was totally trusting of the technology."
Still, the moment highlighted a practical limitation. When weather rolls in, even a sleek, camera-based AI can get cold feet — or at least trigger a manual stop.
See Also: <a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a>
Sheriff's experience has now joined a growing collection of <a href="https://www.reddit.com/r/SelfDrivingCars/comments/1ljxd63/list_of_clips_showing_teslas_robotaxi_incidents/">robotaxi clips posted on Reddit</a>, where users are tracking everything from cars jerking the wheel to stopping mid-road for no reason. One clip shows a robotaxi creeping into oncoming traffic; another shows one driving over a curb.
Tesla's robotaxis operate without LiDAR — the laser-mapping tech used by other AV firms — and rely entirely on cameras and neural networks. Critics argue that weather can interfere with visibility, and Ellie's ride seemed to confirm that Tesla still has work to do when the skies turn gray.
But if the experience showed anything, it's that early adopters aren't just in it for the thrill — they're gathering data. "This is part of the test," Ellie said.
For now, the robotaxi is still learning — and so are the riders. Just make sure to check the forecast before you go driverless.
Read Next: Over the last five years, the price of gold has increased by approximately 83% — Investors like Bill O&#8217;Reilly and Rudy Giuliani are using this platform to <a href="https://www.benzinga.com/money/american-hartford-gold">create customized gold IRAs to help shield their savings from inflation and economic turbulence.&nbsp;</a>
Image: Shutterstock

Elon Musk Fan Took Her First Tesla Robotaxi Ride — But Then It Made Her Get Out And Left Her Stranded 'Cuz It Was About To Rain'

XTI Aerospace, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTIA#NASDAQ">XTIA</a>) ("XTI"), a pioneer in xVTOL and powered-lift aircraft solutions, today announced the completion of a propulsion technical familiarization ("Tech Fam") meeting with the Federal Aviation Administration ("FAA"), another completed step forward in XTI's path to certification of the TriFan 600. The TriFan 600 is XTI's vertical takeoff and landing (VTOL) airplane.
Engineering experts from XTI Aircraft Company, a subsidiary of XTI, and the FAA reviewed the TriFan 600 aircraft's propulsion system and compliance approach for the engines, drive train, fuel system, propellers, engine compartments and structural mounts for the drive train. The Tech Fam addressed key certification areas such as engine fire containment, bird strike impact, cabin occupant safety, fuel management, and instrumentation including sensors to detect system issues

XTIA

XTI Aerospace Completes FAA Propulsion Technical Familiarization Meeting For TriFan 600 VTOL Certification Advancement

Wells Fargo analyst Mike Mayo maintains Goldman Sachs Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) with a Overweight and raises the price target from $650 to $785.

Wells Fargo Maintains Overweight on Goldman Sachs Group, Raises Price Target to $785

Evercore ISI Group analyst Vijay Kumar maintains Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) with a Outperform and raises the price target from $390 to $415.

Evercore ISI Group Maintains Outperform on Stryker, Raises Price Target to $415

Royal Gold, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/RGLD#NASDAQ">RGLD</a>) (together with its subsidiaries, "Royal Gold" or the "Company," "we" or "our") announced today that its wholly owned subsidiary, RGLD Gold AG, sold approximately 40,600 gold equivalent ounces (GEOs)1 comprised of approximately 32,200 ounces of gold, 578,700 ounces of silver and 1,100 tonnes of copper related to its streaming agreements during the three-month period ended June 30, 2025 (the "second quarter"). RGLD Gold AG had approximately 12,700 ounces of gold and 341,000 ounces of silver in inventory at June 30, 2025.
RGLD Gold AG's average realized gold, silver and copper prices for the second quarter were $3,248 per ounce, $32.91 per ounce and $9,210 per tonne ($4.18 per pound), respectively. Cost of sales was approximately $596 per GEO for the second quarter. Cost of sales is specific to the Company's streaming agreements and is the result of RGLD Gold AG's purchase of gold, silver or copper for cash payments at a set contractual price, or a percentage of the prevailing market price of gold, silver or copper when purchased.

RGLD

Royal Gold's Subsidiary RGLD Gold AG Sells 40,600 Gold Equivalent Ounces Including 32,200 Gold, 578,700 Silver Ounces, And 1,100 Tonnes Copper In Q2 2025 At Average Prices Of $3,248/oz Gold, $32.91/oz Silver, And $9,210/tonne Copper

ProKidney Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROK#NASDAQ">PROK</a>) stock is trading higher on Tuesday, with a session volume of 39.8 million compared to the average volume of 1.12 million <a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">as per data from Benzinga Pro</a>.
What happened: The chronic kidney disease (CKD)-focused company reported statistically significant and clinically meaningful positive topline results from the full Group 1 modified intent-to-treat (mITT) population of the Phase 2 REGEN-007 trial of rilparencel in <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">patients with CKD and diabetes</a>.
Rilparencel is an autologous cellular therapy. It is currently being evaluated in the ongoing Phase 3 REGEN-006 (PROACT 1) trial to demonstrate the therapy&#8217;s potential to preserve kidney function in patients with advanced CKD and type 2 diabetes.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/fda/25/06/46171070/fda-raises-manufacturing-concerns-delays-unicycives-kidney-disease-drug-approval" rel="noreferrer noopener">FDA Raises Manufacturing Concerns, Delays Unicycive&#8217;s Kidney Disease Drug Approval</a>
In Group 1 (n=24), kidney function stabilized after receiving rilparencel. The annual decline in estimated glomerular filtration rate (eGFR) slope improved by 78% from -5.8 mL/min/1.73m2 in the pre-injection period to -1.3 mL/min/1.73m2 in the period following the last rilparencel injection.
This 4.6 mL/min/1.73m2 per year difference was statistically significant (p&lt;0.001) <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/g46291838/prokidney-reports-statistically-and-clinically-significant-topline-results-for-the-phase-2-regen-0" rel="noreferrer noopener">and clinically meaningful</a>.
Of the 24 patients in Group 1, 15 (63%) met key Phase 3 PROACT 1 inclusion criteria, and similar efficacy results were observed in this subgroup compared to the full Group 1 results.
In Group 2 (n=25), the annual change in kidney function as measured by eGFR slope was -3.4 mL/min/1.73m2 in the pre-injection period versus -1.7 mL/min/1.73m2 in the period following the last rilparencel injection, resulting in an improvement of 50%, or 1.7 mL/min/1.73m2 per year. This difference was not statistically significant (p=0.085) but suggests evidence of a dose response.
Of the 25 patients in Group 2, 15 (60%) met the re-dosing trigger and received a second rilparencel injection. The median time between the first and second injections in these 15 patients was approximately 11 months.
No rilparencel-related serious adverse events were observed across all patients in the study who received at least one rilparencel injection (n=49). The safety profile was consistent with previously reported study results and comparable to a kidney biopsy.
The company announced that an FDA Type B meeting is scheduled for this summer to confirm ProKidney&#8217;s approach to using eGFR slope as the surrogate endpoint in the ongoing Phase 3 PROACT 1 study, aiming for accelerated approval.
Price Action: At the last check on Tuesday, PROK stock was up 56.6% at $0.95 during the premarket session.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/07/46293606/bp-and-shell-see-new-opportunities-in-libyas-oil-fields" target="_blank" rel="noreferrer noopener">BP And Shell See New Opportunities In Libya&#8217;s Oil Fields</a></li>
</ul>
Photo: Shutterstock

Biotech

Penny Stocks

Health Care

Movers

Trading Ideas

General

PROK

Why Is Penny Stock ProKidney Stock Trading Higher On Tuesday?

Wells Fargo analyst Mike Mayo maintains State Street (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STT#NYSE">STT</a>) with a Overweight and raises the price target from $113 to $121.

Wells Fargo Maintains Overweight on State Street, Raises Price Target to $121

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/08021722/HK-Robotics.jpeg" alt="" class="wp-image-15437" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/08021722/HK-Robotics.jpeg 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/08021722/HK-Robotics-300x200.jpeg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/08021722/HK-Robotics-768x512.jpeg 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
The unknown Hong Kong-listed company's stock has jumped to new highs since repositioning itself earlier this year as a robotics firm
Key Takeaways:
<ul class="wp-block-list">
<li>Hong Kong Robotics' shares have soared on its pivot to robotics, even as it lost HK$140 million last year, its fifth consecutive year in the red</li>
<li>The company rebranded itself earlier this year when it set up a joint venture with Dataa Robotics&nbsp;</li>
</ul>
Listed companies are always chasing the latest trends, and the newest flavor of the day in Hong Kong has been robotics. Shares of companies like Ubtech Robotics (9880.HK), Dobot (2432.HK) and Horizon Robotics (9660.HK), have been feeding off the frenzy, rising 50% or more in the past year. One standout in the group is Hong Kong Robotics Group Holding Ltd. (0370.HK), a Johnny-come-lately whose stock that has soared more than sixfold this year. 
Despite the gains, the company recently released disappointing&nbsp;<a href="https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0627/2025062703254.pdf">annual results</a>&nbsp;that showed its revenue fell 45.6% to a meager HK$116 million ($14.78 million) for its fiscal year through March, as its loss widened 5.3% to HK$138 million. It also reported a HK$11.32 million impairment loss on loans and interest receivable, with additional impairment losses on goodwill and property totaling HK$21.82 million and HK$39.37 million, respectively. Those are hardly what you'd expect from such a stellar stock performer.&nbsp;
<h4 class="wp-block-heading">Robotics joint venture&nbsp;</h4>
Such a dismal performance begs the question of why the stock has surged so much. The story dates back to an agreement signed around Valentine's Day when the company, then called China Best Group,&nbsp;<a href="https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0218/2025021800714.pdf">agreed to form</a>&nbsp;a joint venture with China's&nbsp;Dataa Robotics&nbsp;to explore and develop humanoid robots for civilian uses. China Best Group, which took on its current name in May, was tasked with securing the venture's financing, while Dataa Robotics provided the technology.&nbsp;
Other unknown Hong Kong companies have made similar pivots to take advantage of hot sectors over the years, often through M&amp;A, banking on resulting surges in their stock prices to quickly raise funds. Hong Kong Robotics could be following that playbook, though whether it will ultimately succeed remains to be seen.&nbsp;
When smartphone maker Xiaomi made its unusual move into electric vehicles (EV), unveiling its first model at the end of 2023,&nbsp;<a href="https://thebambooworks.com/with-pedal-to-the-metal-xiaomi-zooms-into-chinas-ev-race/">we concluded</a>&nbsp;that given his strong track record with previous similar forays, founder Lei Jun was very likely to deliver strong results. Today, we'll use a similar approach to assess Hong Kong Robotics' chances of success with its robotics gambit.
<h4 class="wp-block-heading">Disappointing previous results&nbsp;&nbsp;</h4>
We'll start with a look at the company's past record, which is quite spotty. Among other things, it has dabbled in the trading of goods, securities and futures and property. Then, there are forays into heating and cooling supply using geothermal energy, building construction contracting, customized technical support, project management, centralized heating and finance leasing.&nbsp;
The company's market cap was below HK$600 million ($76 million) earlier this year before the joint venture announcement that sparked its stock rally. Its diffuse business mix at that time probably left many investors scratching their heads, wondering where its focus lay, and how it could possibly operate effectively in so many fields.
Moreover, most of those businesses lost money last year, and some were problematic. A case in point was its heating business in Northwest China's Shaanxi province, which had to close and was ultimately sold after failing to meet licensing requirements. Its finance leasing business was also forced to shutter due to regulatory violations and had to be sold, and earlier this year the company announced it would sell its financial holding company.&nbsp;
Meantime, its Shaanxi Jiangwei subsidiary, a building contracting business, got caught up in multiple lawsuits that left some of its assets frozen. Its Shanghai Xuanmei Property Agency unit, a real estate broker, also became embroiled in lawsuits involving 1.06 million yuan ($148,000). So many issues with its various units and day-to-day management are hardly encouraging signals pointing to chances for success from its latest robotics foray.
<h4 class="wp-block-heading">Money-losing partner&nbsp;</h4>
We should also take a closer look at Dataa Robotics, which Hong Kong Robotics is calling the secret weapon behind its coming rebirth. In fact, Dataa Robotics is not a nobody company. It was once a leading Chinese robotics firm, boasting high-tech heavyweights SoftBank and Foxconn as investors and a lofty valuation.&nbsp;
The company was founded in 2015 by Huang Xiaoqing, whose resume included tenures at Bell Labs in the U.S. and as the first head of the China Mobile Communications Research Institute. The company specializes in cloud intelligent robotics technologies, and it raised 1 billion yuan in a 2023 series-C financing that valued it at a lofty 22.3 billion yuan.
But the company burned through those funds to support its nascent humanoid robotics business. It was preparing a U.S. listing in 2019, only have the rug pulled from under it after being blacklisted by the U.S. Department of Commerce. With no cash coming in, the company struggled to stay afloat. Its most recent crisis came in April, when media&nbsp;<a href="https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0627/2025062703254.pdf">reports</a>&nbsp;said it failed to pay hundreds of employees on time in Shanghai, Beijing and Shenzhen, as its Guangzhou operations were disrupted by water shortages and power outages.&nbsp;
More worrisome than its bleeding money is the fact that Dataa Robotics' early investors appear to have abandoned the company and are no longer willing to put in more funds. That raises the question of how much assistance a company that is itself on life support can bring to Hong Kong Robotics, and whether the latter will ever be able to operate the new robotics business profitably.
<h4 class="wp-block-heading">A money race&nbsp;</h4>
Most robotics companies still spend far more money than they generate, making ample liquidity key to staying in business. Locally known venture capitalist Allen Zhu Xiaohu once said that the current cost of humanoid robots far exceeds what customers are willing to pay. What's more, many of their application scenarios are pure creations of manufacturers, often without evidence of underlying demand.
That brings us back to Hong Kong Robotics, which had only HK$50 million in cash as of March, which looks far too small to sustain its new robotics foray. The company announced last month that it would soon enter into four cooperation framework agreements, but how much business can such deals that rely solely on the Hong Kong market really generate?&nbsp;
All that said, the company is still trying to excite investors by playing on the robotics theme, and seems to be having some initial success, based on its huge stock gains. Still, when it will return to profitability is a different issue. The stock surge might embolden the company to try to raise fresh cash in the capital market in the near future. But that could scare off investors, leading to more price volatility. At the end of the day, the stock looks highly speculative right now and is still a far cry from a true robotics play.

Asia

Global

Opinion

Tech

Robotics Frenzy Grips Hong Kong Market And Stocks Ride The Hype; Is The Rally Sustainable?

Evercore ISI Group analyst Vijay Kumar maintains Revvity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RVTY#NYSE">RVTY</a>) with a Outperform and lowers the price target from $116 to $115.

RVTY

Evercore ISI Group Maintains Outperform on Revvity, Lowers Price Target to $115

Evercore ISI Group analyst Daniel Markowitz maintains Repligen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) with a In-Line and lowers the price target from $140 to $130.

RGEN

Evercore ISI Group Maintains In-Line on Repligen, Lowers Price Target to $130

Investigator initiated exploratory clinical study being conducted in Israel pursuant to agreement with collaboration partner, PeriNess
Company evaluating systemic recombinant human DNase I (DNase I) in combination with chemotherapy and immunotherapy platforms for the treatment of pancreatic carcinoma, colorectal cancer and other locally advanced or metastatic solid tumors
FRAMINGHAM, MA / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / July 8, 2025 / <a href="https://pr.report/c3on">Xenetic Biosciences, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XBIO#NASDAQ">XBIO</a>) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its collaboration partner, PeriNess Ltd. (PeriNess), has informed the Company that Bnei Zion Medical Center has commenced patient dosing in an exploratory clinical study of systemic DNase I in combination with FOLFIRINOX for the first line treatment of unresectable, locally advanced or metastatic pancreatic cancer.
PeriNess has informed the Company that the exploratory study is evaluating the safety, biomarker response, pharmacokinetics (PK) and clinical activity of DNase I in combination with first line regimen of FOLFIRINOX chemotherapy in patients with locally advanced or metastatic pancreatic cancer. All patients will receive intravenous infusions of DNase I on Days 1 and 8 of consecutive 14-day cycles. Safety will be continuously evaluated until the end of the study. DNase I pharmacokinetics will be evaluated on Days 1 and 2 of the first FOLFIRINOX cycle and Days 1 and 2 of the third FOLFIRINOX cycle. Neutrophil extracellular traps biomarkers will be evaluated on Day 1 of the first FOLFIRINOX cycle and every 4 weeks thereafter. Clinical activity will be evaluated by the Objective Response Rate (ORR) using Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and Progression-Free Survival (PFS).
 &nbsp;

XBIO

Xenetic Biosciences Announces First Patient Dosing In Exploratory Clinical Study Of Systemic DNase I In Combination With FOLFIRINOX For Advanced Or Metastatic Pancreatic Cancer

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.planet.com%2F&amp;esheet=54285148&amp;newsitemid=20250708787234&amp;lan=en-US&amp;anchor=Planet+Labs+PBC&amp;index=1&amp;md5=21b4cee31f6379e1f674cda9fb5c10fb">Planet Labs PBC</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PL#NYSE">PL</a>), a leading provider of daily data and insights about change on Earth, today announced a new six-figure contract with <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.farmdar.ai%2F&amp;esheet=54285148&amp;newsitemid=20250708787234&amp;lan=en-US&amp;anchor=Farmdar&amp;index=2&amp;md5=5b488bc7541c843f1466fec05de10865">Farmdar</a>, a global agriculture technology company. Through this contract, Farmdar will have access to Planet's deep archive of PlanetScope data, including Planet Basemaps, to inform its crop insights platform.
Planet's satellite imagery will provide critical insights into agricultural operations, enabling more precise crop detection, geographical boundary identification, and arable land mapping. This near-daily data, together with Farmdar's sophisticated AI models, will deliver actionable intelligence to agricultural enterprises worldwide. Since 2022, Farmdar has been relying on Planet's satellite imagery to develop high-precision crop insights at scale. This enhanced access enables Farmdar to drive deeper value for their clientele in multiple categories, specifically for discerning sugar millers globally, demanding high precision insights.

Planet Labs Secures Six-Figure Contract With Farmdar To Provide Satellite Data Enhancing Global Crop Insights And Agricultural Precision

Evercore ISI Group analyst Vijay Kumar maintains Mettler-Toledo Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTD#NYSE">MTD</a>) with a Outperform and raises the price target from $1200 to $1280.

Evercore ISI Group Maintains Outperform on Mettler-Toledo Intl, Raises Price Target to $1280

Press Releases

KalVista Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

KalVista Pharmaceuticals Medical Congress Presentations Highlight Potential of Sebetralstat to Redefine Hereditary Angioedema Management

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals to Present New Sebetralstat Data at the European Academy of Allergy and Clinical Immunology Congress 2025

KalVista Pharmaceuticals Announces FDA Will Not Meet PDUFA Goal Date for Sebetralstat NDA for Hereditary Angioedema Due to FDA Resource Constraints

KalVista Pharmaceuticals Presents New Data at the European Academy of Allergy and Clinical Immunology Congress 2025 on the Efficacy of Sebetralstat for the On-demand Treatment of HAE Attacks Among Patients Receiving Long-Term Prophylaxis

Comments

KalVista Pharma

KalVista Pharma (KALV) Options

KalVista Pharma (NASDAQ:KALV) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL